Flinn, I. W. (2018). The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. American Society of Hematology (ASH).
Chicago Style (17th ed.) CitationFlinn, I. W. The Phase 3 DUO Trial: Duvelisib Vs Ofatumumab in Relapsed and Refractory CLL/SLL. American Society of Hematology (ASH), 2018.
MLA (9th ed.) CitationFlinn, I. W. The Phase 3 DUO Trial: Duvelisib Vs Ofatumumab in Relapsed and Refractory CLL/SLL. American Society of Hematology (ASH), 2018.
Warning: These citations may not always be 100% accurate.